Are Analysts Realistic on Clovis Oncology Now?
Shares of Clovis Oncology dropped after the FDA Oncologic Drugs Advisory Committee voted against its lung cancer drug.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 217
Is PTC Therapeutics on the Road to Recovery?
PTC Therapeutics saw its shares jump late Friday morning on positive news on its nonsense mutation Duchenne muscular dystrophy treatment.
Valeant Debt Downgraded at S&P
Valeant Pharmaceuticals got another dose of bad news Thursday morning. Standard & Poor's Ratings Services dropped the Canadian drugmaker's corporate credit rating
Short Sellers Run for Cover From Major Biotechs
The March 31 short interest data have been compared with the previous report, and short interest decreased across the board in these selected biotech stocks.
Short Sellers Become More Selective in Major Pharma
The March 31 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks short interest was mixed.
Top Biotech Picks Highlight Jefferies Growth Stocks to Buy
A new Jefferies research report highlights their top growth picks for this week, and the list is dominated by top biotech stocks.
Raptor Pharmaceuticals Drops Despite European Launch
Raptor Pharmaceuticals saw its shares sink on Monday after it announced its first commercial sale of Quinsair in Germany and Denmark.
Insys Therapeutics Sinks on Missed Revenue Estimates
Insys Therapeutics watched its stock slide early Monday morning following the release of less-than-favorable revenue estimates.
4 Key Biopharma Movers of the Past Week
Over the past week, Valeant Pharmaceuticals and a few other biotech companies made impressive runs.
Why Depomed Is Rising on Activist Pressure
Depomed saw its stock surge early Friday morning following news of an open letter from activist firm Starboard Value.
3 Stocks With Catalysts That Could Capitalize on Biotech Momentum
If the momentum in biotech can continue, then companies with catalysts within the next 12 to 18 months could get an added boost with any good news.
Ionis Stumbles on FDA Clinical Hold
Ionis Pharmaceuticals made waves in the market on Thursday following a business update on its IONIS-TTR program.
Aeglea BioTherapeutics Enters the Market Way Below Expected Price Range
Aeglea BioTherapeutics entered the market quietly on Thursday morning, with pricing below the expected range of $16 to $18 per share.
Health Care IT Needs Are Growing: 3 Top Stocks to Buy Now
It is no secret that we have an aging population, and it requires more and more hospital treatment, whether it is inpatient or outpatient. This trend is going to go on for some time.
Why Sangamo Shares Could More Than Double
Janney Montgomery Scott reiterated its Buy rating and $15 fair value estimate on Sangamo Biosciences as it brings multiple programs to the clinic this year.